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Abstract
Background: Antibiotic treatment of community-acquired pneumonia (CAP) in children remains mostly empirical because
clinical and paraclinical findings poorly discriminate the principal causes of CAP. Fast response to beta-lactam treatment can
be considered a proxy of pneumococcal aetiology. We aimed to identify the best biological predictor of response to beta-
lactam therapy in children hospitalized for CAP.
Methods: A retrospective, single-centre cohort study included all consecutive patients 1 month to 16 years old hospitalized
in a teaching hospital in Paris, France, because of CAP empirically treated with a beta-lactam alone from 2003 to 2010. Uni-
and multivariate analyses were used to study the ability of routine biological parameters available in the Emergency
Department to predict a favourable response to beta-lactam (defined as apyrexia within 48 hours of treatment onset).
Results: Among the 125 included patients, 85% (106) showed a favourable response to beta-lactam. In multivariate logistic
regression, we found procalcitonin (PCT) the only independent predictor of apyrexia (p=0.008). The adjusted odds ratio for
the decadic logarithm of PCT was 4.3 (95% CI 1.5–12.7). At $3 ng/mL, PCT had 55.7% sensitivity (45.7–65.3), 78.9%
specificity (54.4–93.9), 93.7% positive predictive value (84.5–98.2), 24.2% negative predictive value (14.2–36.7), 2.64 positive
likelihood ratio (1.09–6.42) and 0.56 negative likelihood ratio (0.41–0.77). In the 4 children with a PCT level $3 ng/mL and
who showed no response to beta-lactam treatment, secondary pleural effusion had developed in 3, and viral co-infection
was documented in 1.
Conclusions: PCT is the best independent biologic predictor of favourable response to beta-lactam therapy in children
hospitalized for CAP. Thus, a high PCT level is highly suggestive of pneumococcal aetiology. However, a 3-ng/mL cut-off
does not seem compatible with daily medical practice, and additional research is needed to further define the role of PCT in
managing CAP in children.
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Introduction
Antibiotic treatment of community-acquired pneumonia (CAP)
in children remains mostly empirical because determining the
aetiologic pathogen is difficult in this age group. Clinical findings
[1], chest radiography [2], routine blood analyses (blood cell
count, C-reactive protein [CRP] level) or rapid urinary antigen
detection tests [3] poorly discriminate the principal causes of CAP
(Streptococcus pneumoniae, Mycoplasma pneumoniae and respiratory
viruses). Blood culture results are available only after 2 or 3 days
and are positive in only ,10% of authentic bacterial CAP.
European and American guidelines therefore recommend as the
first choice empirical beta-lactam treatment to target S. pneumoniae
in hospitalized children of all ages [4–8]. In 95% of children with
bacteraemic pneumococcal CAP, apyrexia is reached within 48 hr
of antibiotic treatment [9], and thus, clinical response to beta-
lactam treatment can be considered a proxy of pneumococcal
aetiology.
To date, no biologic predictor of clinical response to beta-
lactam treatment has been found. We aimed to identify predictors
of clinical response among routine biochemical markers available
at admission of children hospitalized with CAP.
Methods
Study design
We conducted a retrospective single-centre hospital-based
cohort study in a teaching hospital in Paris, France. We analyzed
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werehospitalized between January2003andJuly2010forCAPand
empirically treated with beta-lactam monotherapy (amoxicillin, 80–
100 mg/kg/day, or ceftriaxone, 50 mg/kg/day). As in previous
studies, CAP was defined as the association of fever (temperature
$38uC), respiratory symptoms and pulmonary condensation on
chest radiography [10,11]. We excluded children who had received
antibiotics inthe10 days beforeadmission,thosewithanunderlying
chronic respiratory disease except asthma (bronchial ectasia,
bronchopulmonary dysplasia, cystic fibrosis), and those with a
chronic neurologic disease or a known immunodeficiency syn-
drome. Children with empyema or pleural effusion at the time of
CAP diagnosis were excluded because these patients usually show a
delayed response to antibiotherapy [12,13] but children developing
pleural effusion during hospitalization were kept for analysis.
During the study period, the local protocol was to prescribe oral
amoxicillinasfirst-line treatmentforchildrenhospitalizedwith CAP
and intravenous amoxicillin or ceftriaxone when there were
concerns about oral absorption (e.g., because of vomiting).
Outcome
The outcome was clinical response to beta-lactam treatment,
defined as apyrexia within the first 48 hr of treatment (success) or
after 48 hr of treatment (failure) [7,8]. During the study period, all
children underwent axillary temperature measurement every 6 hr.
Temperature was abstracted from clinical charts by one author
blinded to all potential predictors, and apyrexia was defined as 3
consecutive measurements of temperature ,38uC. During the
study period, according to the local protocol, patients were
discharged after 3 consecutive temperature measurements ,38uC.
Potential predictors
During the study period, the local routine protocol for the work-
up of children hospitalized with CAP included, at the time of
arrival in the emergency department, complete blood count
(Coulter counter), CRP level (nephelometry), and procalcitonin
level (PCT; immunoluminometric assay, LUMItest, Brahms
Diagnostica, Berlin, Germany). The manufacturer’s detection
threshold for the PCT assay was 0.1 ng/mL.
Microbiology
Nonsystematic microbiological procedures available during the
study period included blood culture with antibiogram and
minimum inhibitory concentration (MIC) assessment before first
administration of antibiotics, nasopharyngeal swab for fluorescent
viral immunoassay (respiratory syncytial virus [RSV]; influenza
virus A and B; parainfluenza virus 1, 2 and 3; human meta-
pneumovirus [HMPV] and adenovirus), bocavirus and M.
pneumoniae-specific polymerase chain reaction (PCR) assay. When
pleural effusion appearedduringCAP,pleural fluidwasobtained by
pleural puncture or surgical drainage and sent for bacterial analyses
(microscopy direct examination, bacterial culture, S. pneumoniae
antigen detection immunoassay [Binax NOW, Inverness Medical,
Scarborough, ME] and a specific S. pneumoniae PCR).
Statistical analysis
We first described the study population characteristics, includ-
ing the identified pathogens. Values for potential predictors were
compared by Mann-Whitney U test according to clinical response
to beta-lactam treatment. Independent predictors were identified
after adjustment on a multivariate logistic model. In case of strong
correlation between 2 variables (r.0.50, Pearson pairwise
correlation test), we retained the variable with fewer missing data.
When the relationship between clinical response to beta-lactam
treatment and continuous potential predictors was not linear (chi-
square test on deviance difference), continuous variables were
transformed into fractional polynomials of as low degree as
possible [14], and the final model selection involved the Royston &
Altman’s algorithm [15]. The goodness of fit of the model was
assessed with a Hosmer-Lemeshow test [16]. We performed
sensitivity analyses to study the potential effect of the selection of
variables on the main results of the study. For the best identified
predictor on multivariate analysis, we analyzed diagnostic
performance (sensitivity, specificity, likelihood ratios and predic-
tive values) at different rounded thresholds. For each threshold,
sensitivity was defined as the proportion of patients with a value
for a predictor above or equal to the given threshold among those
with clinical response to beta-lactam. Statistical analyses involved
use of Stata/SE 10 (StataCorp, College Station, TX, USA).
Ethics
The Ethical Review Committee ‘‘Comite ´ de Protection des
Personnes Ile de France III’’ has examined the research which was
found to conform to generally accepted scientific principles and
research ethical standards and to be in conformity with the laws
and regulations of the country in which it was performed (File S1).
The waiver of consent was approved by the Institutional Review
Committee (Comite ´ de Protection des Personnes Ile de France III).
Results
Population characteristics and microbiology results
We identified 125 children who met the inclusion criteria. The
mean age (SD) of children was 3.1 years (2.7), 70 were girls and 24
(19%) had asthma. At least one pathogen was identified in 47/123
(38%) of cases. We found 8/87 (9%) positive blood cultures for S.
pneumoniae, and all 8 strains were penicillin sensitive
(MIC,0.06 mg/mL). All patients with positive blood culture
results for S. pneumoniae showed apyrexia within 48 hr of treatment
onset. These patients had higher PCT levels than those with
negative blood culture results (median 9.4 vs. 3.2 ng/mL, p=0.06,
Mann-Whitney U test). PCR results for M. pneumoniae were positive
in 5/64 (8%) of cases, and nasopharyngeal swab results were
positive for viruses in 35/109 (32%) of cases, with RSV found in
17/35 (49%) cases, influenza A in 9/35 (26%) cases, adenovirus in
3/35 (9%) cases, enterovirus in 2/35 (6%) cases, and influenza B,
parainfluenza 3, HMPV and bocavirus in 1/35 (3%) cases each.
The patient with a positive bocavirus PCR was admitted on day 4
of fever and then showed apyrexia at the end of day 3 of beta-
lactam treatment. S. pneumoniae co-infection was suspected in this
patient on the basis of a positive urinary antigen test result. In 3
children, secondary pleural effusion developed during hospitaliza-
tion; 2 underwent surgical pleural drainage and 1 ultrasound-
guided pleural puncture. In 2 of these 3 children, pleural fluid
results remained negative, but the third case had positive results on
S. pneumoniae antigen detection immunoassay of pleural fluid.
Clinical response to beta-lactam treatment
Most of the children, 106/125 (85%), showed clinical response
to beta-lactam treatment. Among the 19 other patients, 4 received
macrolide treatment after the first 48 hr of beta-lactam treatment
and then showed stable apyrexia within 48 more hours. Two of
them had positive PCR results for M. pneumoniae (among 10
patients tested for M. pneumoniae by PCR). In all, only 1/125
patients was readmitted in the same hospital within 15 days after
discharge because of febrile relapse. This patient was considered a
non-responder in the analyses. Among 125 patients, 38 (30%)
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(49%) intravenous ceftriaxone. Response or not to antibiotic
treatment did not differ by antibiotic (amoxicillin vs. ceftriaxone,
p=0.90) or route of administration (oral vs. intravenous, p=0.51).
Children with a response or not to beta-lactam treatment did not
differ significantly in age (median 2.7 vs. 2.2 years, p=0.43) or
prevalence of asthma (19.8% vs. 15.8%, p=0.68).
Prediction of clinical response to beta-lactam treatment
The median neutrophil count and PCT level were significantly
higher in children with than without a response to beta-lactam
treatment (14790 vs. 12330/mm
3 and 3.7 vs. 0.7 ng/mL,
respectively, p,0.05, Table 1). The median white blood cell
(WBC) count and CRP level were higher but not significantly in
children with than without a treatment response (18850 vs.
15400/mm
3, p=0.06; 155 vs. 59 mg/L, p=0.13, respectively).
The WBC and neutrophil counts were highly correlated (r=0.92,
p,0.001). Neutrophil count contained several missing data (22/
125; 18%), so neutrophil count was excluded from the multivariate
logistic model. Because the relationship between clinical response
to beta-lactam treatment and PCT level as a continuous variable
was non-linear (p=0.02), PCT level was transformed into a first-
degree fractional polynomial by natural logarithmic transforma-
tion. No transformation was needed for CRP level or WBC count
(p=0.87 and p=0.16 respectively). After adjustment for CRP
level, WBC and PCT level in a logistic model, only PCT remained
independently and significantly associated with clinical response to
beta-lactam treatment (p=0.008). The adjusted odds ratio for the
decadic logarithm of PCT was 4.3 (95% CI 1.5–12.7). Every 10-
fold increase in PCT level was associated with 4.3-fold odds of
beta-lactam treatment being successful. The fit of the logistic
model was good (p=0.67). We conducted a sensitivity analysis to
evaluate the potential effect of not including age in the
multivariate model and found no change in the main results of
the study: age as a dichotomous variable (,2 vs. $2 yr) or a
continuous variable after transformation into fractional polyno-
mials was not associated with response to antibiotics treatment
(p=0.66 for both), and PCT remained the only predictor of
success after adjustment for age. We also conducted a sensitivity
analysis that included neutrophil count instead of WBC count in
the multivariate model. The main results of the study were stable:
PCT remained the only predictor associated with response to
antibiotics treatment, with a slight increase in the adjusted odds
ratio (from 4.3 [1.5–12.7] to 5.4 [1.6–17.5]).
PCT for the prediction of apyrexia
The detailed performance of PCT level in predicting apyrexia is
in Table 2. Among 63 children with a PCT level $3 ng/mL, 59
(94%) showed apyrexia within the first 48 hr of treatment and 47
(75%) within the first 24 hr. Among the 4 patients with a PCT
level $3 ng/mL who showed no response to beta-lactam
treatment, secondary pleural effusion developed in 3, and
bocavirus infection mixed with suspected S. pneumoniae infection
(positive urinary antigen detection test) was documented in 1
(Figure 1). With a 3-ng/mL cutoff, the performance of PCT was
55.7 (95% CI 45.7–65.3) and 78.9% (54.4–93.9) for sensitivity and
specificity, respectively; 93.7% (84.5–98.2) and 24.2 (14.2–36.7)
for positive and negative predictive values, respectively; 2.64
(1.09–6.42) and 0.56 (0.41–0.77) for positive and negative
likelihood ratio, respectively; and 4.7 (1.5–14.4) odds ratio.
Discussion
This is the first study aiming to identify biological predictors of
clinical response to antibiotic treatment in children hospitalized
with CAP. As compared with WBC count, neutrophil count and
CRP level, PCT level was the best marker routinely tested that
predicted apyrexia. These results are consistent with those of 5 of 7
studies investigating the ability of PCT level to distinguish the
different aetiologic pathogens of CAP in children [11,17–22]. In
our study, 94% of children with a PCT level $3 ng/mL showed
apyrexia within the first 48 hr of beta-lactam treatment, and 75%
apyrexia within the first 24 hr of treatment. In 3 of the 4 children
with a PCT level $3 ng/mL who showed no response to beta-
lactam treatment, secondary pleural effusion had developed and in
the other one, bocavirus infection was documented. A 3-ng/mL
cutoff for PCT provided high specificity, positive predictive value
and odds ratio. These results confirm the potential usefulness of
PCT in estimating the efficacy of the pneumococcal conjugate
vaccine among children [23] and determining the eligibility of
children for clinical trials of CAP as has been proposed for adults
[3,24]. A recent study showed that a PCT-based approach could
reduce antibiotic consumption in children with CAP [25]. Though
our results suggest that a high PCT level is associated with
pneumococcal aetiology, the likelihood ratios that we found for
PCT were insufficient for everyday medical decision making and
further investigation is needed to develop a PCT-based clinical
decision rule. The PCT cut-off of $3 ng/ml should not be
considered a threshold to identify pneumococcal CAP in daily
clinical practice. Lower operational thresholds were reported in
studies of adults [26] and children [25]. However, a PCT cut-off of
$3 ng/ml is probably specific enough to be used as an eligibility
criterion in studies estimating the efficacy of the pneumococcal
conjugate vaccine in children [23] and for clinical trials of
antibiotics in CAP [24].
Clinical response to beta-lactam treatment (i.e., reaching or not
apyrexia within the first 48 hr of antimicrobial treatment) seemed
an interesting outcome to predict because persistence of fever after
Table 1. Analysis of predictors according to clinical response to beta-lactam treatment.
Apyrexia within 48 hr of treatment Apyrexia after 48 hr of treatment
N Mean Median IQR Mean Median IQR p
WBC count (/mm




103 15941 14790 8610–21740 10966 12330 7200–16380 0.04
CRP level (mg/L) 125 163 155 51–242 119 59 27–266 0.13
PCT level (ng/mL) 125 8.7 3.7 1–9.4 3.1 0.7 0.2–2.9 0.002
Abbreviations: WBC, white blood cell; CRP, C-reactive protein; PCT, procalcitonin; IQR, interquartile range.
doi:10.1371/journal.pone.0036927.t001
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failure and leads to new investigations (e.g., new chest radiography)
and/or to antibiotherapy modification. Predicting a fast response to
beta-lactam therapy might be considered a proxy to predict S.
pneumonia as a causative pathogen in CAP. Toikka et al. showed that
among 85 children with blood-culture–proven pneumococcal CAP,
most (95%) showed apyrexia within the first 48 hr of antibiotic
treatment [9]. In this Finnish study, as in ours, patients with no
response to antibiotic treatment within 48 hr showed pleural
effusion developed or an underlying chronic condition (chronic
encephalopathy or respiratory disease). In another of our studies,
most children (92%) with documented pneumococcal CAP showed
defervescence within 24 h with beta-lactam monotherapy [10]. We
considered clinical response to antibiotherapy within 48 hr of
treatment onset a proxy for pneumococcal aetiology, but viral
infections may resolve during the same time. We obtained only
indirect evidence of the aetiology of CAP in most patients, and our
results should be considered with caution. The fact that children
with pneumococcal CAP mostly become afebrile within 48 hr of
antibiotic treatment only indirectly supports the conclusion that
most patients with CAP who became afebrile within 48 hr actually
had pneumococcal infection.
The main limitation to this study is its design as a retrospective
analysis, which could suggest loss of accuracy in data collection,
especially clinical characteristics (e.g., apyrexia) and missing data
(as observed for 18% of the neutrophil count). Furthermore, we
defined CAP by the association of fever, respiratory symptoms and
condensation on chest radiography, but chest radiographs were
Figure 1. Distribution of procalcitonin (PCT) level according to clinical response to beta-lactam treatment. The short, bold,
horizontal lines are the median for each group.
doi:10.1371/journal.pone.0036927.g001
Table 2. Predictive performance of procalcitonin (PCT) level in clinical response to beta-lactam treatment.
PCT Sensitivity (%) Specificity (%) PPV (%) NPV (%) PLR NLR
0.3 91.5 [84.5–96.0] 31.6 [12.6–56.6] 88.2 [80.6–93.6] 40.0 [16.3–67.7] 1.34 [0.98–1.83] 0.27 [0.11–0.67]
0.5 87.7 [79.9–93.3] 42.1 [20.3–66.5] 89.4 [81.9–94.6] 38.1 [18.1–61.6] 1.52 [1.03–2.24] 0.29 [0.14–0.61]
1 79.2 [70.3–86.5] 57.9 [33.5–79.7] 91.3 [83.6–96.2] 33.3 [18.0–51.8] 1.88 [1.10–3.22] 0.36 [0.21–0.61]
2 65.1 [55.2–74.1] 63.2 [38.4–83.7] 90.8 [81.9–96.2] 24.5 [13.3–38.9] 1.77 [0.96–3.24] 0.55 [0.36–0.85]
3 55.7 [45.7–65.3] 78.9 [54.4–93.9] 93.7 [84.5–98.2] 24.2 [14.2–36.7] 2.64 [1.09–6.42] 0.56 [0.41–0.77]
4 48.1 [38.3–58.0] 84.2 [60.4–96.6] 94.4 [84.6–98.8] 22.5 [13.5–34.0] 3.05 [1.06–8.77] 0.62 [0.47–0.81]
5 42.5 [32.9–52.4] 84.2 [60.4–96.6] 93.8 [82.8–98.7] 20.8 [12.4–31.5] 2.69 [0.93–7.77] 0.68 [0.53–0.88]
10 23.6 [15.9–32.8] 94.7 [74.0–99.9] 96.2 [80.4–99.9] 18.2 [11.1–27.2] 4.48 [0.65–31.13] 0.81 [0.69–0.94]
PCT thresholds are in ng/mL.
Numbers in square brackets are 95% confidence intervals.
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio, NLR, negative likelihood ratio.
doi:10.1371/journal.pone.0036927.t002
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estimate any inter-rater reliability. These non-differential biases
and the absence of an a priori sample size calculation could have
led to loss of power, but we were still able to find several
statistically significant differences.
This study included children hospitalized because of the severity
of their clinical features or because of their young age (mean age:
3.1 vs. median 4.1 years in published series in the literature)
[10,27–33]. This lower age could have resulted in an over-
representation of viral CAP and an under-representation of M.
pneumoniae CAP. The consequences of this selection bias cannot be
precisely estimated because published epidemiological series of
CAP in children show strong heterogeneity (different epidemio-
logical contexts, different microbiological investigation methods).
Likewise, we studied only children with severe CAP requiring
hospitalization. We did not include children who had complicated
CAP (i.e., empyema or pleural effusion on admission) or children
with underlying chronic respiratory disease (except asthma).
Further clinical research is needed to confirm that our findings
also apply to these particular populations.
Another limitation of this study is that selection bias could have
occurred because we included children hospitalized for CAP and
empirically treated with a beta-lactam monotherapy during the first
48 hr for suspected S. pneumoniae infection. Indeed, in our study, the
treating physician in charge of the patient in the emergency
department was free to choose the antibiotherapy that he felt to be
the most adapted to the patient’s condition on the basis of implicit
epidemiologic, clinical and paraclinical findings, including PCT
level. This bias limits the reproducibility of our results to another
population, because of the single-centre design of our study.
In conclusion, PCT level was found the only predictor of the
clinical response to beta-lactam treatment in children hospitalized
for CAP. Our data indirectly shows that a serum level of PCT
$3 ng/mL is suggestive of pneumococcal CAP, but this threshold
seems too high to be implemented in daily clinical practice to
identify pneumococcal CAP. However, this threshold might be
useful in epidemiological surveillance studies and clinical trials for
CAP in children.
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